Molecular mechanism of mitoquinol mesylate in mitigating the progression of hepatocellular carcinoma-in silico and in vivo studies
| Autor: | Akinrinade George Ayankojo, Timothy Olajire Olaniyi, Fatimah B. Abdulkareem, Rahmat Adetutu Adisa, Titilola Samuel, Lateef Adegboyega Sulaimon, Ireoluwa Yinka Joel |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
0301 basic medicine
MitoQ biology Chemistry Succinate dehydrogenase Active site Cell Biology Mitochondrion medicine.disease Ligand (biochemistry) Biochemistry Molecular biology KEAP1 03 medical and health sciences chemistry.chemical_compound 030104 developmental biology 0302 clinical medicine In vivo 030220 oncology & carcinogenesis biology.protein medicine Liver cancer Molecular Biology |
| Zdroj: | Journal of cellular biochemistryREFERENCES. |
| ISSN: | 1097-4644 |
| Popis: | The safety and efficacy of mitoquinol mesylate (MitoQ) in attenuating the progression of hepatocellular carcinoma (HCC) in Wistar rats has been reported. However, the binding modes for MitoQ as well as its molecular mechanisms in cirrhosis and liver cancer have not been fully investigated. This study sought to understand the structural and molecular mechanisms of MitoQ in modulating the expression of nuclear factor erythroid 2-related factor 2 (Nrf2) and mitochondrial succinate dehydrogenase (SDH) in cirrhotic-HCC rats. The research indicates that the upregulated Nrf2 expression in cirrhotic-HCC rats was significantly (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text